332 related articles for article (PubMed ID: 28057891)
21. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
22. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
23. Akt-regulated pathways in prostate cancer.
Majumder PK; Sellers WR
Oncogene; 2005 Nov; 24(50):7465-74. PubMed ID: 16288293
[TBL] [Abstract][Full Text] [Related]
24. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
25. PTEN in liver diseases and cancer.
Peyrou M; Bourgoin L; Foti M
World J Gastroenterol; 2010 Oct; 16(37):4627-33. PubMed ID: 20872961
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of PTEN loss in cancer: It's all about diversity.
Álvarez-Garcia V; Tawil Y; Wise HM; Leslie NR
Semin Cancer Biol; 2019 Dec; 59():66-79. PubMed ID: 30738865
[TBL] [Abstract][Full Text] [Related]
27. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F
Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540
[TBL] [Abstract][Full Text] [Related]
28. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
29. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
30. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
31. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
32. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
34. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
35. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
36. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines.
Sharrard RM; Maitland NJ
Cell Signal; 2007 Jan; 19(1):129-38. PubMed ID: 16842970
[TBL] [Abstract][Full Text] [Related]
37. PTEN and the PI3-kinase pathway in cancer.
Chalhoub N; Baker SJ
Annu Rev Pathol; 2009; 4():127-50. PubMed ID: 18767981
[TBL] [Abstract][Full Text] [Related]
38. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
Wen YG; Wang Q; Zhou CZ; Qiu GQ; Peng ZH; Tang HM
Oncol Rep; 2010 Jul; 24(1):89-95. PubMed ID: 20514448
[TBL] [Abstract][Full Text] [Related]
39. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells.
Rhee YH; Chung PS; Kim SH; Ahn JC
Biochem Biophys Res Commun; 2014 May; 447(4):557-62. PubMed ID: 24525130
[TBL] [Abstract][Full Text] [Related]
40. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]